ImaCor Names Peter Pellerito President and CEO
“I was delighted to be asked to build another exciting company globally. I was particularly impressed with the team’s domain expertise and passion to drive efficacy in this healthcare environment. This unique and elegant application helps answer questions of cardiac filling and function at the most critical time within the ICU and perioperative environments. It is our vision to have ClariTEE probes in ICU patients all around the world,” said Pellerito.
“We are excited to have someone with Peter’s experience in innovative technology and direct industry expertise to lead our company,” said Scott Roth, MD, founder and chief medical officer of ImaCor. “We are confident that Peter’s past success in building global businesses will accelerate our growth and the emerging application of TEE monitoring.”
William Doyle of WFD Ventures, ImaCor’s chairman, adds, “Peter has been extremely successful growing businesses and developing new clinical applications in the arena of medical imaging. We are very confident that Peter will continue this trend and establish a global business leveraging ImaCor’s core technology.”
About ImaCor
ImaCor Inc. is a privately held company headquartered in Uniondale, NY. The company designs, manufactures, and distributes advanced solutions for TEE monitoring in the critical care environment for the purpose of improving patient outcomes. The Company manufactures the ClariTEE ™ probe, the only miniaturized, indwelling probe for TEE monitoring. ZuraTM and ClariTEETM are trademarks of ImaCor, Inc. For more information, please visit our website at www.imacormonitoring.com
Contact:
ImaCor, Inc. Dipak Rajhansa, 516-393-0970